These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 25952728

  • 1. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M.
    Eur J Pharmacol; 2015 Aug 15; 761():383-90. PubMed ID: 25952728
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS, Huisman EL, Punekar YS, Karabis A.
    Int J Chron Obstruct Pulmon Dis; 2015 Aug 15; 10():2495-517. PubMed ID: 26604738
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H, Mailänder C, May C, Baier M, Kirsten AM.
    Pulm Pharmacol Ther; 2017 Feb 15; 42():13-20. PubMed ID: 27940287
    [Abstract] [Full Text] [Related]

  • 5. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
    Gavaldà A, Ramos I, Carcasona C, Calama E, Otal R, Montero JL, Sentellas S, Aparici M, Vilella D, Alberti J, Beleta J, Miralpeix M.
    Pulm Pharmacol Ther; 2014 Aug 15; 28(2):114-21. PubMed ID: 24928173
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.
    Chest; 2012 Mar 15; 141(3):745-752. PubMed ID: 21903737
    [Abstract] [Full Text] [Related]

  • 8. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG.
    COPD; 2010 Oct 15; 7(5):331-6. PubMed ID: 20854047
    [Abstract] [Full Text] [Related]

  • 9. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
    Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG.
    Respir Med; 2015 Oct 15; 109(10):1305-11. PubMed ID: 26303336
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D.
    Lancet; 2017 May 13; 389(10082):1919-1929. PubMed ID: 28385353
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
    Singh D, Scuri M, Collarini S, Vezzoli S, Mariotti F, Muraro A, Acerbi D.
    Int J Chron Obstruct Pulmon Dis; 2017 May 13; 12():2001-2014. PubMed ID: 28744115
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
    Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D'Andrea P.
    BMC Pulm Med; 2014 Jan 17; 14():4. PubMed ID: 24438744
    [Abstract] [Full Text] [Related]

  • 17. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2017 Jan 17; 12():1731-1740. PubMed ID: 28652725
    [Abstract] [Full Text] [Related]

  • 18. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
    Buhl R, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2012 Jan 17; 7():729-41. PubMed ID: 23118536
    [Abstract] [Full Text] [Related]

  • 19. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
    Manoharan A, Morrison AE, Lipworth BJ.
    Lung; 2016 Apr 17; 194(2):259-66. PubMed ID: 26758884
    [Abstract] [Full Text] [Related]

  • 20. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
    Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D.
    Lancet Respir Med; 2013 May 17; 1(3):199-209. PubMed ID: 24429126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.